Loading...

COVID‑19 Alert: Stay home if you feel unwell. If you have a fever, cough and difficulty breathing, seek medical attention. Follow the directions of your local health authority. Source WHO

We have a lockdown, "Working from HOME" Please reach out for any queries at: help@alliedmarketresearch.com & Int'l : +1-503-894-6022, (UK) : +44-845-528-1300

New

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market by Product Type (DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine, by Age Group (Adult and Pediatric), and by End User (Hospitals, Clinics, and Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2020–2027

A03468
Pages: 193
May 2020 | 2780 Views
 
Author(s) : Ankita Sonar and Onkar Sumant
Tables: 28
Charts: 17
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Diphtheria, Pertussis, And Tetanus (dtp) Vaccine Market

Request Now !

The diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019, and is expected to reach $ 7,054.4million by 2027, with a CAGR of 5.1%, during the forecast period.

DTP refers to diphtheria, tetanus, and pertussis. Vaccines used for DTP are immunization drugs initially administered at the age of two to produce acquired immunity against DTP (Diphtheria, Tetanus, and Pertussis). Since 1974, DTP vaccines have been part of the Expanded Programme of Immunisation (EPI) vaccination schedule. DTP as a standalone vaccine has been declined substantially. Rise in demand for tetravalent and subsequently pentavalent combination vaccines has principally contributed to this shift. The increased combination product demand has largely been led by GAVI (Global Alliance for Vaccines and Immunizations) funding for other DTP-containing vaccines. 

Diphtheria,-Pertussis-and-Tetanus-Vaccine-Market-2020-2027

Get more information on this report : Request Sample Pages

With high DTP vaccination rates of 86%, globally in 2018, the incidences of diphtheria and tetanus have been well controlled. However, the disease continues to cause illness globally. According to the Centre for Disease control and prevention, in 2016, reported about 7,100 cases of diphtheria and 1248 cases of pertussis to the World Health Organization globally. Owing to the rise in number of cases during late spring and early summer further drives the DTP vaccine market demand for DTP vaccines, especially for advanced vaccines.

Growth in government and non-government initiatives for vaccine development, coupled with surge in awareness among people regarding these vaccines boosts the DTP vaccine market growth. However, high cost of vaccine development and inadequate access to vaccines in under developed countries restrict the market growth. Moreover, emerging markets offer lucrative opportunities for the key market players.

Product segment review

On the basis of product, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in demand for DTaP vaccines and growth in adoption of pertussis vaccines around the globe drives the growth of this segment. The WHO suggests that inoculation helps in preventing 2 to 3 million deaths every year against tetanus, diphtheria, whooping cough, and measles. Only few cases of respiratory diphtheria were reported by the CDC from 1996 to 2016, post the introduction of vaccines. However, inadequately vaccinated or unvaccinated travelers are at more risk of acquiring infections. Thus, governments globally have made it mandatory to immunize travelers visiting countries with infectious diseases to prevent further spread of infectious agents. Likewise, as per the stats provided in 2015 by the WHO, approximately 85% infants received three doses of DTaP vaccine across the globe. Rise in adoption of pertussis vaccine, high birth rates, growth in initiatives taken by governments, and insurance and reimbursement scenarios in different countries provided by governments drive the DTaP vaccines market growth globally.

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
By Product

Your browser does not support the canvas element.

DTaP holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Age Group segment review

On the basis of age group, the DTP vaccines market is segmented into pediatrics vaccines and adult vaccines. Vaccines for adults are likely to show high growth potential due to rise in incidences of infectious diseases among adults. In addition, growth in research and development and strong product pipeline is also likely to increase the growth of the segment during the forecast period. However, the pediatrics segment dominated the market due to high demand of DTP vaccine among infants. The potential size of pediatrics vaccines segment is based on the facts that birthrate is increasing globally, which boosts the doses for pediatrics vaccines and as per the WHO norms infants worldwide have to receive 3 doses of DTP vaccine necessarily to cope with the life threatening diseases.

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
By Age Group

Your browser does not support the canvas element.

Pediatric segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Region segment review

By region, the diphtheria, pertussis, and tetanus (DTP) vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2019, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. Asia-Pacific is expected to witness highest growth rate for the DTP vaccine market throughout the forecast period. Increase in demand for DTP vaccines, growth in awareness of newer technologies and rise in population awareness are prime factors that supplement the adoption of DTP vaccine.

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
By End User

Your browser does not support the canvas element.

Hospitals holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

The report provides a comprehensive analysis of the key players operating in the global DTP Vaccine market, namely AJ Vaccines, Bionet-Asia, GlaxoSmithKline plc (GSK), Johnson & Johnson, Massbiologics, Meiji Holdings Co., Ltd. (KM biologics co., Ltd.), Merck & Co., Inc., Panacea Biotec Ltd., Sanofi, and Serum Institute of India Pvt. Ltd.

Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 6.1% during 2020-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current DTP Vaccine market trends and forecast estimations from 2019 to 2027, which assists to identify the prevailing market opportunities. 

  • An in-depth DTP vaccine market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.

  • Region-wise and country-wise market conditions are comprehensively analyzed in this report.

  • The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2027, in terms of value.

  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

  • Key market players within the DTP Vaccine market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global DTP Vaccine market.

Key Market Segments

By Product Type

  • DTaP
  • TD
  • Tdap

By Age Group

  • Adult
  • Pediatric

By End User

  • Hospitals
  • Clinics
  • Vaccination Centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research

1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top player positioning, 2019

3.3.Porter’s five forces analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Rise in initiatives by pharma companies to enhance vaccine R&D
3.4.1.2.Growth in awareness among people about the advantages of DTP vaccines

3.4.2.Restraints

3.4.2.1.Inadequate access to vaccines in under developed countries
3.4.2.2.High cost of vaccine development

3.4.3.Opportunities

3.4.3.1.Innovative vaccine technologies

CHAPTER 4:DTP VACCINES MARKET, BY PRODUCT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.DTaP Vaccines

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.TD Vaccines

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Tdap Vaccines

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:DTP VACCINES MARKET, BY AGE GROUP

5.1.Overview

5.1.1.Market size and forecast

5.2.Adults

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Pediatrics

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

CHAPTER 6:DTP VACCINES MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast
6.2.2.Market analysis, by country

6.3.Clinics

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Vaccination Centers

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:DTAP VACCINES MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by product
7.2.3.Market size and forecast, by age group
7.2.4.Market size and forecast, by end user
7.2.5.Market size and forecast, by country

7.2.5.1.U.S. market size and forecast, by product
7.2.5.2.U.S. market size and forecast, by age group

7.2.6.Market size and forecast, by end users

7.2.6.1.Canada market size and forecast, by product
7.2.6.2.Canada market size and forecast, by age group

7.2.7.Market size and forecast, by end users

7.2.7.1.Mexico market size and forecast, by product
7.2.7.2.Mexico market size and forecast, by age group

7.2.8.Market size and forecast, by end users

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by product
7.3.3.Market size and forecast, by age group
7.3.4.Market size and forecast, by end user
7.3.5.Market size and forecast, by country

7.3.5.1.Germany market size and forecast, by product
7.3.5.2.Germany market size and forecast, by age group

7.3.6.Market size and forecast, by end users

7.3.6.1.France market size and forecast, by product
7.3.6.2.France market size and forecast, by age group

7.3.7.Market size and forecast, by end users

7.3.7.1.UK market size and forecast, by product
7.3.7.2.UK market size and forecast, by age group

7.3.8.Market size and forecast, by end users

7.3.8.1.Italy market size and forecast, by product
7.3.8.2.Italy market size and forecast, by age group

7.3.9.Market size and forecast, by end users

7.3.9.1.Rest of Europe market size and forecast, by product
7.3.9.2.Rest of Europe market size and forecast, by age group

7.3.10.Market size and forecast, by end users

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast, by product
7.4.3.Market size and forecast, by age group
7.4.4.Market size and forecast, by end users
7.4.5.Market size and forecast, by country

7.4.5.1.Japan market size and forecast, by product
7.4.5.2.Japan market size and forecast, by age group

7.4.6.Market size and forecast, by end users

7.4.6.1.China market size and forecast, by product
7.4.6.2.China market size and forecast, by age group

7.4.7.Market size and forecast, by end users

7.4.7.1.Australiamarket size and forecast, by product
7.4.7.2.Australia market size and forecast, by age group

7.4.8.Market size and forecast, by end users

7.4.8.1.India market size and forecast, by product
7.4.8.2.India market size and forecast, by age group

7.4.9.Market size and forecast, by end users

7.4.9.1.Rest of Asia Pacificmarket size and forecast, by product
7.4.9.2.Rest of Asia Pacific market size and forecast, by age group

7.4.10.Market size and forecast, by end users

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast, by product
7.5.3.Market size and forecast, by age group
7.5.4.Market size and forecast, by end users
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil market size and forecast, by product
7.5.5.2.Brazil market size and forecast, by age group

7.5.6.Market size and forecast, by end users

7.5.6.1.South Africa market size and forecast, by product
7.5.6.2.South Africa market size and forecast, by age group

7.5.7.Market size and forecast, by end users

7.5.7.1.Rest of LAMEA market size and forecast, by product
7.5.7.2.Rest of LAMEA market size and forecast, by age group
7.5.8.Market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AJ VACCINES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio

8.2.BIONET-ASIA

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio

8.3.GLAXOSMITHKLINE PLC (GSK)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.JOHNSON & JOHNSON

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.MASSBIOLOGICS

8.5.1.Company overview
8.5.2.Company snapshot1
8.5.3.Product portfolio

8.6.MEIJI HOLDINGS CO., LTD. (KM BIOLOGICS CO., LTD.)

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.MERCK & CO., INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.PANACEA BIOTEC LTD.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SANOFI

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.SERUM INSTITUTE OF INDIA PVT. LTD

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio

LIST OF TABLES

TABLE 01.GLOBAL DTP VACCINES MARKET, BY PRODUCT TYPE 2019–2027, ($MILLION)
TABLE 02.DTAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION
TABLE 03.TD VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 04.TDAP VACCINES MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 05.GLOBAL DTP VACCINES MARKET, BY AGE GROUP, 2019–2027, ($MILLION)
TABLE 06.DTP VACCINES MARKET FOR ADULTS, BY REGION, 2019–2027, ($MILLION)
TABLE 07.DTP VACCINES MARKET FOR PEDIATRICS, BY REGION, 2019–2027, ($MILLION)
TABLE 08.GLOBAL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 09.DTP MARKET FOR HOSPITALS, BY REGION, 2019–2027, ($MILLION)
TABLE 10.DTP MARKET FOR CLINICS, BY REGION, 2019–2027, ($MILLION)
TABLE 11.DTP MARKET FOR VACCINATION CENTERS, BY REGION, 2019–2027, ($MILLION)
TABLE 12.DTP VACCINES MARKET, BY REGION 2019–2027, ($MILLION)
TABLE 13.NORTH AMERICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 14.NORTH AMERICA VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 15.NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 16.NORTH AMERICA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 17.U.S. DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 18.U.S. DTAP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 19.U.S. DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 20.CANADA DTP VACCINES MARKET, BY PRODUCT, 2019-2026, ($MILLION)
TABLE 21.CANADA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 22.CANADA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 23.MEXICO DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 24.MEXICO DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 25.MEXICO DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 26.EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 27.EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 28.EUROPE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 29.EUROPE DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 30.GERMANY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 31.GERMANY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 32.GERMANY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 33.FRANCE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 34.FRANCE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 35.FRANCE DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 36.UK DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 37.UK DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 38.UK DTP VACCINES MARKET, BY END USER, , 2019-2027, ($MILLION)
TABLE 39.ITALY DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 40.ITALY DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 41.ITALY DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 42.REST OF EUROPE DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 43.REST OF EUROPE DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 44.REST OF EUROPE DTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 45.ASIA-PACIFIC DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 46.ASIA-PACIFIC DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 47.ASIA-PACIFIC DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 48.ASIA-PACIFIC DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 49.JAPAN DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 50.JAPAN DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 51.JAPAN DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 52.CHINA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 53.CHINA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 54.CHINA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 55.AUSTRALIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 56.AUSTRALIA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 57.AUSTRALIADTAP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 58.INDIADTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 59.INDIADTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 60.INDIADTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 61.REST OF ASIA PACIFICDTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 62.REST OF ASIA PACIFICDTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 63.REST OF ASIA PACIFICDTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 64.LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 65.LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 66.LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 67.LAMEA DTP VACCINES MARKET, BY COUNTRY, 2019-2027, ($MILLION)
TABLE 68.BRAZIL DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 69.BRAZIL DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 70.BRAZIL DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 71.SOUTH AFRICA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 72.SOUTH AFRICA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 73.SOUTH AFRICA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 74.REST OF LAMEA DTP VACCINES MARKET, BY PRODUCT, 2019-2027, ($MILLION)
TABLE 75.REST OF LAMEA DTP VACCINES MARKET, BY AGE GROUP, 2019-2027, ($MILLION)
TABLE 76.REST OF LAMEA DTP VACCINES MARKET, BY END USER, 2019-2027, ($MILLION)
TABLE 01.AJ VACCINES: COMPANY SNAPSHOT
TABLE 02.AJ VACCINE: PRODUCT PORTFOLIO
TABLE 03.BIONET-ASIA: COMPANY SNAPSHOT
TABLE 04.BIONET-ASIA: PRODUCT PORTFOLIO
TABLE 05.GSK: COMPANY SNAPSHOT
TABLE 06.GLAXOSMITHKLINE PLC.: OERATING SEGMENT
TABLE 07.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 08.J&J: COMPANY SNAPSHOT
TABLE 09.J&J: OPERATING SEGMENTS
TABLE 10.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 11.MASSBIOLOGICS: COMPANY SNAPSHOT
TABLE 12.MASSBIOLOGICS: PRODUCT PORTFOLIO
TABLE 13.MEIJI.: COMPANY SNAPSHOT
TABLE 14.MEIJI HOLDINGS CO., LTD..: OPERATING SEGMENTS
TABLE 15.MEIJI HOLDINGS CO., LTD.: PRODUCT PORTFOLIO
TABLE 16.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 17.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 18.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 19.PANACEA BIOTEC LTD..: COMPANY SNAPSHOT
TABLE 20.PANACEA BIOTEC LTD..: OPERATING SEGMENTS
TABLE 21.PANACEA BIOTEC LTD.: PRODUCT PORTFOLIO
TABLE 22.PANACEA BIOTEC LTD..: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 23.SANOFI: COMPANY SNAPSHOT
TABLE 24.SANOFI: OERATING SEGMENT
TABLE 25.SANOFI: PRODUCT PORTFOLIO
TABLE 26.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 27.SII.: COMPANY SNAPSHOT
TABLE 28.SII.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.DTP VACCINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DTP VACCINE MARKET, 2019
FIGURE 03.TOP PLAYER POSITIONING, 2019
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.LOW THREAT OF SUBSTITUTIONS
FIGURE 07.MODERATE THREAT OF NEW ENTRANTS
FIGURE 08.MODERATE COMPETITIVE RIVALRYS
FIGURE 09.GLOBAL DTP VACCINE MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 10.COMPARATIVE SHARE ANALYSIS OF DTAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 11.COMPARATIVE SHARE ANALYSIS OF TDAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF TDAP VACCINES MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR ADULTS, BY COUNTRY, 
2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR PEDIATRICS, BY COUNTRY, 
2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 
2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR CLINICS, BY COUNTRY, 
2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DTP VACCINES MARKET FOR VACCINATION CENTERS, BY COUNTRY,  2019 & 2027 (%)
FIGURE 01.GSK NET SALES, 2017–2019 ($MILLION)
FIGURE 02.GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 03.GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 04.JOHNSON & JOHNSON: NET SALES, 2017–2019 ($MILLION)1
FIGURE 05.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 06.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 07.MEIJI HOLDINGS CO., LTD.: NET SALES, 2017–2019 ($MILLION)
FIGURE 08.MEIJI HOLDINGS CO., LTD.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 09.MERCK & CO., INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 10.MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 11.MERCK & CO., INC.: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 12.PANACEA BIOTEC LTD.: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.PANACEA BIOTEC LTD.: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 14.PANACEA BIOTEC LTD.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 15.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 16.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 17.SANOFI: REVENUE SHARE BY REGION, 2019 (%)

 
 

The global diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% during the forecast period. 

Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough). A 0.5 mL booster should be given intramuscularly to children between the ages of 4 and 6. 

In May, 2012, the WHO launched the ‘Global Vaccine Action Plan (GVAP),’ which was authorized by 194 member states of the World Health Assembly. This plan aims to strengthen standard immunization to check the transmission of communicable diseases through periodic assessments and evaluate the achieved progress, which is measured in terms of national vaccination coverage target goals, which are constructively met. In addition, rise in involvement of government and non-government organizations in this field is expected to provide an impactful boost to the market growth.

Improvements in healthcare infrastructure, growth in vaccination awareness, and rise in incidences of preventable diseases drive the growth of the global DTP vaccines market. However, a number of limitations are associated with DTP vaccines such as lack of medical aids in underdeveloped regions and high cost investments in vaccine manufacturing, which restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 5.1% from 2020 to 2027. On the contrary, emerging markets are anticipated to offer significant growth opportunities for market players in the future

The global DTP vaccine market is segmented into product type, age group, end user, and region. By product, it is divided into DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is classified into adult and pediatric. Further, on the basis of end user, it is bifurcated into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2027, which assists to identify the prevailing market opportunities. 

  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

  • A comprehensive analysis of the factors that drive and restrain the growth of the global DTP vaccine market is provided.

  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

Key Market Segments

By Product Type

  • DTaP
  • TD
  • Tdap

By Age Group

  • Adult
  • Pediatric

By End User

  • Hospitals
  • Clinics
  • Vaccination Centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Rest of LAMEA
 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total value of Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market was $4,758.8 million in 2019.

A. The forecast period in the report is from 2020-2027.

A. The market value of Diphtheria, Tetanus, and Pertussis (DTP) Vaccine in 2020 was $4,993.04 million.

A. The base year calculated is 2019 in the report.

A. As per the study GlaxoSmithKline plc (GSK) and Sanofi are the top market share holders in global Diphtheria, Tetanus, and Pertussis (DTP) Vaccine market

A. Rise in initiatives by pharma companies to enhance vaccine R&Das well as rise in healthcare expenditure are expected to drive the market growth during the forecast period.

A. The growth % of the Diphtheria, Tetanus, and Pertussis (DTP) Vaccine is 5.1%.

A. DTaP vaccines segment holds the maximum market share.

A. DTaP and TD vaccines segment is are the key matured markets growing in the Diphtheria, Tetanus, and Pertussis (DTP) Vaccine market

A. Rise in adoption of pertussis vaccine, high birth rates, growth in initiatives taken by government, and insurance and reimbursement scenarios in different countries provided by governments drive the DTaP vaccines market growth globally

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts